Phase 1 Dose Escalating and Expansion Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects With Advanced or Metastatic Solid Tumors
Latest Information Update: 27 Aug 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; ONO 4578 (Primary)
- Indications Colorectal cancer; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Biomarker; First in man
- Sponsors Ono Pharmaceutical
- 23 Aug 2024 Planned End Date changed from 1 Sep 2025 to 1 Jan 2026.
- 23 Aug 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Jan 2026.
- 20 Jan 2024 Results (n=51) evaluating safety profile in patients with mCRC presented at the 2024 Gastrointestinal Cancers Symposium